Lei L. Chen

Lei L. Chen, MD, PhD

Lei L. Chen MD PhD MD Anderson, Immunotherapy

Lei Chen, M.D., Ph.D. and Professor of Medicine at the Huntsman Cancer Institute at the University of Utah and her colleagues have planned a new trial to do just that.

Chen"The two major obstacles of durable remission in cancer patients are acquired drug-resistant clones and tumor stem cells" according to Chen.
...
According to Dr. Chen:
...
"If given at the right dose, [with the] right timing, combined with the right drug, interferon , holds the greatest potential in breaking immune tolerance and shifting to immune stimulation against patients' tumors," said Chen, "with pegylated interferon , 2b we expect much improved toxicity."
...
Dr. Chen at Huntsman Cancer Institute plans to enroll approximately thirty GIST patients for a phase II trial.
...
Chen and colleagues have taken the challenge of drug-resistant clones and tumor stem cells and designed a trial combining targeted therapy and immunotherapy.They are aiming high for a long-term remission or cure and are truly offering a new and interesting opportunity to GIST patients.

Dr. Lei L. Chen is the primary investigator at the Huntsman Cancer Institute in Salt Lake City, Utah.Dr. Chen theorizes that Gleevec causes GIST cell death which in turn marks GIST cells for immune system response.

Lei L. Chen, MD, PhD

Professor, Department of Internal Medicine

Lei Chen, MD, PhD is a professor in the Division of Oncology, Department of Internal Medicine at the University of Utah School of Medicine.She is also an investigator and medical oncologist with special interests in sarcoma and gastrointestinal cancer at Huntsman Cancer Institute.

Her research interests include oncogene signal transduction (a biological process that creates functional changes within the cell leading to malignancy), mechanisms of drug resistance, and the discovery of new targets for cancer therapy.A current clinical trial with which she is involved combines targeted therapy (Gleevec) and immunotherapy (PEG-Intron) to eradicate drug-resistant cells as well as tumor stem cells, with the hope of durable remission or cure of gastrointestinal stromal tumors (GIST).

Chen received her PhD in biochemistry from City University of New York and her medical degree at Albert Einstein College of Medicine in New York.She completed a residency at Montefiore Hospital and Medical Center and an oncology fellowship at Memorial Sloan-Kettering Cancer Center.Before joining Huntsman Cancer Institute in 2006, she served as a faculty member at M.D.Anderson Cancer Center in Texas.

Lei L. Chen, MD, PhD, Internal Medicine

Lei L. Chen, MD, PhD
...
Lei Chen, MD, PhD is a professor in the Division of Oncology, Department of Internal Medicine at the University of Utah School of Medicine.She is also an investigator and medical oncologist with special interests in sarcoma and gastrointestinal cancer at Huntsman Cancer Institute.

Her research interests include oncogene signal transduction (a biological process that creates functional changes within the cell leading to malignancy), mechanisms of drug resistance, and searching for new targets for cancer therapy.One of her current clinical pursuits involves designing innovative clinical trials that combine targeted therapy and immunotherapy to eradicate drug-resistant cells and tumor stem cells, with the hope for durable remission or cure.Chen has numerous publications and invited articles in translational and clinical sarcoma research.

Chen received her PhD in biochemistry from City University of New York and her medical degree at Albert Einstein College of Medicine in New York.She completed a residency at Montefiore Hospital and Medical Center and an oncology fellowship at Memorial Sloan-Kettering Cancer Center.Before joining Huntsman Cancer Institute in 2006, she served as a faculty member at M.D.Anderson Cancer Center in Texas.